Status:
COMPLETED
Elimination of CD4+CD25+ Regulatory T Cells in Patients With Hepatocellular Carcinoma
Lead Sponsor:
Hannover Medical School
Conditions:
Advanced HCC
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
It has been shown that patients with advanced HCC have an increased frequency of CD4+CD25+ regulatory T cells. These cells might suppress tumor-specific immune responses. Cyclophosphamide has been sho...
Eligibility Criteria
Inclusion
- adequate WBC
- adequate liver and kidney function
- no immunodeficiency
- ECOG \< 2
Exclusion
- advanced liver cirrhosis
- severe cardiopulmonary diseases
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2008
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00396682
Start Date
February 1 2007
End Date
December 1 2008
Last Update
February 4 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medizinische Hochschule Hannover
Hanover, Germany, 30655